Diadema Partners’s Aardvark Therapeutics AARD Stock Holding History

Diadema Partners’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,882	Closed	-$208K	–	219
2025 Q4	$208K	Buy	+15,882	New	+$198K	0.04%	126

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Diadema Partners's AARD Position: Q1 2026 in Review

Diadema Partners sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 15,882 shares — an estimated $208K sold.

Diadema Partners first reported a position in AARD in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

Diadema Partners reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 15,882 Aardvark Therapeutics shares in Q1 2026, an estimated $208K.
Diadema Partners first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 1 quarter.
Diadema Partners's Aardvark Therapeutics position peaked at $208K in Q4 2025.
79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.